- Home
- DFP vs URGN Comparison
DFP vs URGN Comparison
Compare DFP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFP
- URGN
- Stock Information
- Founded
- DFP 2013
- URGN 2004
- Country
- DFP United States
- URGN United States
- Employees
- DFP N/A
- URGN N/A
- Industry
- DFP Investment Managers
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- DFP Finance
- URGN Health Care
- Exchange
- DFP Nasdaq
- URGN Nasdaq
- Market Cap
- DFP 420.8M
- URGN 465.9M
- IPO Year
- DFP N/A
- URGN 2017
- Fundamental
- Price
- DFP $19.47
- URGN $9.67
- Analyst Decision
- DFP
- URGN Strong Buy
- Analyst Count
- DFP 0
- URGN 7
- Target Price
- DFP N/A
- URGN $37.21
- AVG Volume (30 Days)
- DFP 56.2K
- URGN 499.1K
- Earning Date
- DFP 01-01-0001
- URGN 05-12-2025
- Dividend Yield
- DFP 6.73%
- URGN N/A
- EPS Growth
- DFP N/A
- URGN N/A
- EPS
- DFP N/A
- URGN N/A
- Revenue
- DFP N/A
- URGN $90,398,000.00
- Revenue This Year
- DFP N/A
- URGN $38.65
- Revenue Next Year
- DFP N/A
- URGN $118.69
- P/E Ratio
- DFP N/A
- URGN N/A
- Revenue Growth
- DFP N/A
- URGN 9.29
- 52 Week Low
- DFP $15.45
- URGN $8.94
- 52 Week High
- DFP $19.31
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- DFP 46.14
- URGN 41.45
- Support Level
- DFP $18.63
- URGN $8.94
- Resistance Level
- DFP $19.61
- URGN $10.83
- Average True Range (ATR)
- DFP 0.42
- URGN 0.79
- MACD
- DFP 0.00
- URGN -0.07
- Stochastic Oscillator
- DFP 59.07
- URGN 29.67
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.